Health Tech

Partially, and only for specific things. Wearables have credible, regulator-cleared features for irregular heart rhythm, sleep apnoea signals and fall detection. Broad early warning of infection or disease is research-grade signal, not diagnosis.

AI supports diagnosis; it does not own it. Cleared tools read scans, flag findings and triage in clinical settings, and general models are startlingly good at plausible differentials. Regulation, liability and error modes mean a clinician signs off, and a chatbot is not a doctor.

Not to a standard you should treat clinically. Wearables are good at heart rhythm, sleep staging and trends, and irregular-rhythm alerts have genuinely sent people to a doctor in time. Cuffless blood pressure is approximate and drifts; needle-free glucose remains unsolved despite two decades of confident announcements.

Barely. A small number of countries have approved cultivated meat products, sold in limited restaurants or trial retail. Production volumes are tiny and costs remain far above conventional meat, so this is a novelty rather than a supply chain.

In research, users genuinely feel touch through nerve-interfaced prosthetics, and it measurably improves control. Commercially available advanced prosthetics offer excellent grip patterns but only limited or no true sensory feedback, and cost is a major barrier.

For a small number of clinical trial participants, yes — and it is life-changing. Implanted interfaces let people with paralysis move cursors, type and control devices by intent. For everyone else, non-invasive consumer headsets remain crude: a few commands, lots of calibration.

No. Researchers print tissue patches, cartilage, skin grafts and organoids used for drug testing, and a few simple structures have been implanted in trials. A printed, vascularised, transplantable kidney or heart is not close.